Compare Aurora Cannabis Inc (ACB) vs Agora Inc (API) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Agora, Inc. (API) trades at $4.46, up 7.47% today, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.01, beating expectations, and shows improving fundamentals with 2025 revenue of $141.06M and net income of $9.53M. Recent news highlights its Q2 2026 earnings report scheduled for August 13, 2026.

Outlook is positive with analyst consensus at 60% buy, supported by a low P/B of 0.68 and strong cash flow growth. Risks include high P/E of 50.68 and competitive pressures in AI technology. The stock offers value potential if earnings growth continues, but volatility may persist near-term.